Pharmascience Inc. – Product Pipeline Review – H2 2011

Document Sample
Pharmascience Inc. – Product Pipeline Review – H2 2011 Powered By Docstoc
					     Pharmascience Inc. – Product Pipeline Review – H2
                           2011

                                                                                          Reference Code: GMDHC01755CDB


                                                                                                 Publication Date: NOV 2011




Pharmascience Inc. – Product Pipeline Review – H2 2011                                       GMDHC01755CDB/ Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Pharmascience Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Pharmascience Inc. Snapshot .................................................................................................................................................................................. 6
      Pharmascience Inc. Overview ............................................................................................................................................................................ 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Pharmascience Inc. – Research and Development Overview ................................................................................................................................... 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Pharmascience Inc. – Pipeline Review ..................................................................................................................................................................... 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      Pharmascience Inc. – Pipeline Products Glance ...............................................................................................................................................10
      Pharmascience Inc. Clinical Stage Pipeline Products ........................................................................................................................................10
            Phase II Products/Combination Treatment Modalities .................................................................................................................................10
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................11
      Pharmascience Inc.–Early Stage Pipeline Products ..........................................................................................................................................12
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................12
Pharmascience Inc. – Drug Profiles .........................................................................................................................................................................13
      AEG33773 ........................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      AEG35156 + Carboplatin + Paclitaxel ...............................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
      AEG35156 + Sorafenib .....................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
      AEG40826 ........................................................................................................................................................................................................16
            Product Description ....................................................................................................................................................................................16
            Mechanism of Action...................................................................................................................................................................................16
            R&D Progress .............................................................................................................................................................................................16
      AEG41174 ........................................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
      AEGXXXXX ......................................................................................................................................................................................................18
            Product Description ....................................................................................................................................................................................18
            Mechanism of Action...................................................................................................................................................................................18
            R&D Progress .............................................................................................................................................................................................18
Pharmascience Inc. – Pipeline Analysis ..................................................................................................................................................................19
      Pharmascience Inc. – Pipeline Products by Therapeutic Class .........................................................................................................................19
      Pharmascience Inc. - Pipeline Products By Target ............................................................................................................................................20
      Pharmascience Inc. – Pipeline Products by Route of Administration .................................................................................................................22




Pharmascience Inc. – Product Pipeline Review – H2 2011                                                                                                        GMDHC01755CDB/ Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Pharmascience Inc. – Product Pipeline Review



      Pharmascience Inc. – Pipeline Products by Molecule Type ...............................................................................................................................23
Pharmascience Inc. – Recent Pipeline Updates .....................................................................................................................................................24
Pharmascience Inc. - Dormant Projects ...................................................................................................................................................................27
Pharmascience Inc. - Discontinued Pipeline Products .............................................................................................................................................28
      Discontinued Pipeline Product Profiles ..............................................................................................................................................................28
            AEG35156 + Ara-C + Idarubicin..................................................................................................................................................................28
            AEG35156 + Gemcitabine ..........................................................................................................................................................................28
            AEG35156 + Paclitaxel ...............................................................................................................................................................................29
Pharmascience Inc. – Locations And Subsidiaries ...................................................................................................................................................30
      Head Office .......................................................................................................................................................................................................30
      Other Locations & Subsidiaries .........................................................................................................................................................................30
Recent Developments .............................................................................................................................................................................................31
            Jul 31, 2008: Aegera Initiates A Fifth Phase 1 And 2 Clinical Trial For AEG35156 ......................................................................................31
            May 30, 2008: Human Genome Sciences Initiates First Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Solid Tumors ..............31
            Jan 26, 2010: Aegera Initiates Randomized Phase II Study With AEG35156 To Treat Hepatocellular Carcinoma Patients.........................32
            Jan 26, 2010: Aegera Therapeutics Initiates Phase 2 Study Of AEG35156 For The Treatment Of Hepatocellular Carcinoma ....................33
            Nov 25, 2008: Aegera Therapeutics' Phase 1/2 Clinical Trial Results Of AEG35156, Selected For Oral Presentation At 2008 ASH Annual
            Meeting.......................................................................................................................................................................................................33
            Nov 23, 2009: Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial Of Lead IAP Inhibitor HGS1029 In
            Advanced Lymphoid Tumors ......................................................................................................................................................................34
            Nov 19, 2009: Aegera Therapeutics Initiates A Randomized Phase 2B Study With AEG35156 For The Treatment Of Acute Myeloid
            Leukemia (AML) .........................................................................................................................................................................................34
            Jul 19, 2010: Aegera Reports Survival Data From Phase I Portion Of Phase I- II Study Of AEG35156 In Combination With Sorafenib.......35
            Mar 18, 2008: Aegera Initiates Phase I Clinical Trial Of AEG33773 ............................................................................................................36
            Nov 17, 2005: Aegera’s AEG35156 Phase 1 Oncology Trial Demonstrates Target Response In Cancer Patients ......................................36
            May 16, 2005: Aegera Therapeutics Announces The Results Of Antisense XIAP, AEG35169 ....................................................................37
            Feb 15, 2006: Aegera Initiates Third Clinical Trial For AEG35156 – A Targeted Therapeutic For Oncology ................................................38
            Jun 10, 2008: Aegera Therapeutics Collaboration With Human Genome Sciences Leads To The Initiation Of A Phase 1 Clinical Trial With
            Lead IAP Inhibitor HGS1029 And Receipt Of First Milestone Payment .......................................................................................................38
            Jan 09, 2006: AEGERA Receives Approval From Health Canada To Initiate A Phase I Clinical Trial For AEG33783 .................................3
				
DOCUMENT INFO
Description: Pharmascience Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Pharmascience Inc. - Product Pipeline Review - H2 2011” provides data on the Pharmascience Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pharmascience Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Pharmascience Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Pharmascience Inc. - Brief Pharmascience Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Pharmascience Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Pharmascience Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Pharmascience Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Pharmascience Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Pharmascience Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Pharmascience Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensin
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries